Literature DB >> 8251846

Postmarketing study of cardiovascular adverse reactions associated with sumatriptan.

J P Ottervanger1, T B van Witsen, H A Valkenburg, B H Stricker.   

Abstract

Mesh:

Substances:

Year:  1993        PMID: 8251846      PMCID: PMC1679316          DOI: 10.1136/bmj.307.6913.1185

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Coronary vasospasm and sumatriptan.

Authors:  B H Stricker
Journal:  BMJ       Date:  1992-07-11

2.  Coronary vasospasm induced by subcutaneous sumatriptan.

Authors:  F Willett; N Curzen; J Adams; M Armitage
Journal:  BMJ       Date:  1992-05-30

3.  Transmural myocardial infarction with sumatriptan.

Authors:  J P Ottervanger; H J Paalman; G L Boxma; B H Stricker
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

4.  The safety and tolerability of sumatriptan: an overview.

Authors:  E G Brown; C A Endersby; R N Smith; J C Talbot
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

5.  Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.

Authors:  P D MacIntyre; B Bhargava; K J Hogg; J D Gemmill; W S Hillis
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

  5 in total
  3 in total

1.  Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.

Authors:  J P Ottervanger; T B van Witsen; H A Valkenburg; D E Grobbee; B H Stricker
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 2.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 3.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.